Immunophotonics is excited to announce that a leading academic medical center that combines high-quality complex patient care with innovative scientific research, received authorization to proceed with recruitment to conduct a clinical trial combining Immunophotonics’ investigational drug IP-001 with AngioDynamics’ advanced ablation devices. This trial will explore the power of IP-001 following thermal ablation or irreversible electroporation (IRE) and assess the efficacy and immune response for the treatment of colorectal cancer (CRC) at different stages of the disease.

Co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) extend special recognition to Prof. Martijn Meijerink, Danielle Vos, and Hester Scheffer for their pivotal roles in conducting a clinical trial to further evaluate the safety and efficacy of this combinational treatment to further propel the field of Interventional Immuno-Oncology™.

Read more: Official Press Release